---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-103023"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:59:36.324409+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion Q2 net loss narrows to $20.7M, raises $42.8M, pipeline advances

## Summary
- Net loss $20.7M (Q2 2025) vs $37.3M (Q2 2024); R&D expenses halved to $16.6M.
- Raised ~$42.8M gross from public offering; cash runway extended into H2 2026.
- Icovamenib at ADA 2025: durable HbA1c reduction, enhanced beta-cell function; combo with semaglutide showed superior glycemic control and weight loss with lean mass preservation.
- BMF-650 achieved up to 15% weight loss in obese monkeys; IND submission on track for H2 2025.
- Workforce reduced; quarterly expenses expected ~40% lower; oncology program BMF-500 ended, seeking partnerships.

## SEC filing metadata
- accession: 0000950170-25-103023
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000095017025103023/0000950170-25-103023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000095017025103023/bmea-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-103023
- JSON: https://secwatch.observer/filing/0000950170-25-103023.json
- Plain text: https://secwatch.observer/filing/0000950170-25-103023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.